BidaskClub cut shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) from a hold rating to a sell rating in a report issued on Tuesday, July 25th.
Other equities research analysts also recently issued research reports about the company. Maxim Group cut their price objective on Achillion Pharmaceuticals from $8.00 to $5.00 and set a buy rating for the company in a report on Tuesday, April 25th. Zacks Investment Research raised Achillion Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, July 18th. Jefferies Group LLC reissued a hold rating on shares of Achillion Pharmaceuticals in a report on Wednesday, April 26th. Robert W. Baird increased their price objective on Achillion Pharmaceuticals from $5.00 to $10.00 and gave the company an outperform rating in a report on Monday, April 24th. Finally, Leerink Swann raised Achillion Pharmaceuticals from a market perform rating to an outperform rating and increased their price objective for the company from $4.00 to $6.00 in a report on Thursday, May 18th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $8.25.
Achillion Pharmaceuticals (NASDAQ:ACHN) traded up 5.982% during trading on Tuesday, hitting $4.695. 1,794,270 shares of the stock were exchanged. The firm’s 50 day moving average price is $4.39 and its 200-day moving average price is $4.13. Achillion Pharmaceuticals has a 1-year low of $3.15 and a 1-year high of $9.49. The stock’s market cap is $642.09 million.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). During the same period last year, the company posted ($0.14) earnings per share. On average, analysts anticipate that Achillion Pharmaceuticals will post ($0.63) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Achillion Pharmaceuticals, Inc. (ACHN) Downgraded by BidaskClub” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://stocknewstimes.com/2017/08/12/bidaskclub-downgrades-achillion-pharmaceuticals-inc-achn-to-sell-updated-updated.html.
Large investors have recently made changes to their positions in the stock. State Street Corp increased its stake in shares of Achillion Pharmaceuticals by 40.1% in the fourth quarter. State Street Corp now owns 5,121,160 shares of the biopharmaceutical company’s stock valued at $21,153,000 after buying an additional 1,465,723 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Achillion Pharmaceuticals by 204.9% in the second quarter. Dimensional Fund Advisors LP now owns 1,868,968 shares of the biopharmaceutical company’s stock valued at $8,579,000 after buying an additional 1,255,962 shares in the last quarter. Norges Bank acquired a new stake in shares of Achillion Pharmaceuticals during the fourth quarter valued at about $4,623,000. Senzar Asset Management LLC acquired a new stake in shares of Achillion Pharmaceuticals during the second quarter valued at about $4,966,000. Finally, Vanguard Group Inc. increased its stake in shares of Achillion Pharmaceuticals by 7.2% in the first quarter. Vanguard Group Inc. now owns 9,585,823 shares of the biopharmaceutical company’s stock valued at $40,357,000 after buying an additional 646,415 shares in the last quarter. 70.83% of the stock is owned by institutional investors and hedge funds.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.